Addressing unmet clinical needs with targeted therapeutic radiopharmaceuticals
PIPELINE
Blue Earth Therapeutics is developing next generation targeted radiotherapeutics to transform the clinical management of patients with cancer. The company has acquired exclusive worldwide rights to radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) targeted technology for therapeutic use and has a research programme initially focused on prostate cancer. The rhPSMA molecule is being investigated in two programmes; one using the beta emitting radioisotope lutetium 177 (177Lu), and one using the alpha emitter actinium 225 (225Ac).
OUR PIPELINE
Blue Earth Therapeutics is investigating the use of the rhPSMA molecule for therapy with the addition of an alpha or beta emitting radioisotope.
|
PRODUCT/CANDIDATE
|
DISEASE/THERAPEUTIC AREA
|
APPLICATION
|
PRECLINICAL
|
PHASE 1
|
PHASE 2
|
PHASE 3
|
|
177Lu-rhPSMA-10.1 |
Prostate Cancer |
Radiopharmaceutical Therapy |
|
|
|
|
|
225Ac-rhPSMA-10.1 |
Prostate Cancer |
Radiopharmaceutical Therapy |
|
|
|
|
177Lu-rhPSMA-10.1 is currently being studied to evaluate its safety profile, tolerability, radiation dosimetry and anti-tumour activity in men with metastatic castrate-resistant prostate cancer (NCT05413850).
https://www.clinicaltrials.gov/ct2/show/NCT05413850?term=NCT05413850
PP-UK-0650 / October 2023
